Page last updated: 2024-12-05
propylhexedrine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
propylhexedrine: was heading 1976-94 (see under PROPYLAMINES 1976-90); use PROPYLAMINES to search PROPYLHEXEDRINE 1976-94; alpha-adrenergic stimulant used extensively in nasal decongestant inhalers [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 7558 |
| CHEMBL ID | 2105275 |
| CHEBI ID | 134783 |
| SCHEMBL ID | 28537 |
| SCHEMBL ID | 20780004 |
| MeSH ID | M0225274 |
Synonyms (94)
| Synonym |
|---|
| methyl-(1-methyl-2-cyclohexylethyl)amine |
| 101-40-6 |
| propylhexedrin |
| 1-cyclohexyl-2-(methylamino)propane |
| benzedrex |
| hydromethamphetamine |
| dristan |
| (cyclohexaneethyl)amine, n-.alpha.-dimethyl- |
| propylhexadrine |
| propylhexedrine |
| wln: l6tj a1y1&m1 |
| obesin |
| nsc-32410 |
| n-.alpha.-(dimethylcyclohexane)ethylamine |
| chp-depot |
| nsc32410 |
| cyclohexaneethylamine, n-.alpha.-dimethyl- |
| cyclohexaneethanamine,.alpha.-dimethyl- |
| hexahydrodesoxyephedrine |
| 1-cyclohexyl-n-methylpropan-2-amine |
| (cyclohexaneethyl)amine, n-alpha-dimethyl- |
| dristan inhaler |
| (+-)-n,alpha-dimethylcyclohexaneethylamine |
| brn 3194303 |
| beta-cyclohexyl-isopropylmethylamin [german] |
| 1-cyclohexyl-n-methyl-2-propanamine |
| cyclohexaneethylamine, alpha,n-dimethyl- |
| 1-cyclohexyl-2-methylaminopropan [german] |
| cyclohexaneethanamine, n,alpha-dimethyl-, (+-)- |
| cyclohexaneethanamine, n,alpha-dimethyl-, (+-) |
| nsc 32410 |
| einecs 202-939-3 |
| n,alpha-dimethylcyclohexaneethylamine |
| cyclohexaneethanamine, n,.alpha.-dimethyl- |
| dristan inhaler (tn) |
| D05637 |
| propylhexedrine (usp/inn) |
| CHEBI:134783 |
| DB06714 |
| STK664138 |
| NCGC00182042-01 |
| cas-101-40-6 |
| dtxcid303526 |
| (+/-) propylhexedrine |
| dtxsid1023526 , |
| tox21_113077 |
| CHEMBL2105275 |
| propylhexedrine dl-form |
| dl-propylhexedrine |
| AKOS005172629 |
| 3595-11-7 |
| FT-0674106 |
| propylhexedrine [usp:inn:ban] |
| propilhexedrina |
| propilhexedrina [inn-spanish] |
| propilesedrina [dcit] |
| 1-cyclohexyl-2-methylaminopropan |
| beta-cyclohexyl-isopropylmethylamin |
| propylhexedrinum |
| 3-12-00-00108 (beilstein handbook reference) |
| propylhexedrinum [inn-latin] |
| einecs 222-741-0 |
| propilesedrina |
| lqu92iu8ll , |
| unii-lqu92iu8ll |
| propylhexedrine [inn] |
| propylhexedrine [who-dd] |
| propylhexedrine dl-form [mi] |
| propylhexedrine [vandf] |
| propylhexedrine [mart.] |
| (+/-)-n,.alpha.-dimethylcyclohexaneethanamine |
| propylhexedrine [usp monograph] |
| AB01331925-02 |
| SCHEMBL28537 |
| n,.alpha.-dimethylcyclohexaneethylamine |
| cyclohexaneethylamine, .alpha.,n-dimethyl- |
| cyclohexaneethanamine, n,.alpha.-dimethyl-, (.+/-.) |
| (.+/-.)-n,.alpha.-dimethylcyclohexaneethylamine |
| .alpha.,n-dimethylcyclohexaneethylamine |
| n-methyl-1-cyclohexylisopropylamine |
| cyclohexaneethanamine, n,alpha-dimethyl- |
| (1-cyclohexylpropan-2-yl)(methyl)amine |
| Q408704 |
| SCHEMBL20780004 |
| NCGC00182042-04 |
| NCGC00182042-03 |
| EN300-135610 |
| propilhexedrina (inn-spanish) |
| propylhexedrinum (inn-latin) |
| propylhexedrine (usp monograph) |
| propylhexedrine (mart.) |
| (+/-)-n,alpha-dimethylcyclohexaneethanamine |
| propylhexedrine (usp:inn:ban) |
| benzedrex09-19-2014 |
Research Excerpts
Overview
Propylhexedrine is a potent alpha-adrenergic drug available as a nasal decongestant. Drug abusers sometimes extract and inject into a central vein.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Propylhexedrine is a potent α-adrenergic sympathomimetic amine found in nasal decongestant inhalers." | ( A drug toxicity death involving propylhexedrine and mitragynine. Holler, JM; Levine, B; Magluilo, J; McDonough-Bender, PC; Solomon, CJ; Vorce, SP, 2011) | 1.37 |
| "Propylhexedrine is a potent alpha-adrenergic drug available as a nasal decongestant, which drug abusers sometimes extract and inject into a central vein. " | ( Airway compromise and delayed death following attempted central vein injection of propylhexedrine. Burton, BT; McGirr, JG; Perez, J, ) | 1.8 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Misuse of this drug can lead to serious and potentially fatal cardiac and psychiatric adverse effects." | ( Abuse or Misuse of OTC Decongestant Produces Serious Adverse Effects. Aschenbrenner, DS, 2021) | 0.62 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| secondary amino compound | A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (1)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 56.2341 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Ceullar Components (1)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| virion membrane | Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 57.85
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (57.85) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 3 (25.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||